Efinopegdutide

Efinopegdutide
Clinical data
Other names	MK-6024
Legal status
Legal status	Investigational;
Identifiers
CAS Number	2055640-93-0 ;
UNII	DR6P1M58PO ;

Last updated September 29, 2025

Efinopegdutide (MK-6024) is a dual agonist of the glucagon and GLP-1 receptors. It is being developed by Merck for non-alcoholic fatty liver disease. It was also developed for type 2 diabetes and obesity but these indications were discontinued.^[1]^[2]^[3]^[4]

References

↑ Romero-Gómez, Manuel; Lawitz, Eric; Shankar, R. Ravi; Chaudhri, Eirum; Liu, Jie; Lam, Raymond L.H.; Kaufman, Keith D.; Engel, Samuel S.; Bruzone, Santiago Oscar; Coronel, Maria Jimena; Gruz, Fernando M.; MacKinnon, Ignacio; George, Jacob; Muller, Kate; Lee, Samuel S. (2023-06-22). "A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease". Journal of Hepatology. 79 (4): 888–897. doi: 10.1016/j.jhep.2023.05.013 . hdl: 10261/349752 . ISSN 0168-8278. PMID 37355043.
↑ Novikoff, Aaron; Müller, Timo D. (July 2023). "The molecular pharmacology of glucagon agonists in diabetes and obesity". Peptides. 165 171003. doi: 10.1016/j.peptides.2023.171003 . PMC 10265134 . PMID 36997003.
↑ Zhihong, Yao; Chen, Wang; Qianqian, Zhu; Lidan, Sun; Qiang, Zhou; Jing, Han; Wenxi, Wang; Bhawal, Ruchika (April 2023). "Emerging roles of oxyntomodulin-based glucagon-like peptide-1/glucagon co-agonist analogs in diabetes and obesity". Peptides. 162 170955. doi:10.1016/j.peptides.2023.170955. PMID 36669563. S2CID 255969171.
↑ Jepsen, Mathies M.; Christensen, Mikkel B. (3 July 2021). "Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity". Expert Opinion on Emerging Drugs. 26 (3): 231–243. doi:10.1080/14728214.2021.1947240. PMID 34176426. S2CID 235661514.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] Romero-Gómez, Manuel; Lawitz, Eric; Shankar, R. Ravi; Chaudhri, Eirum; Liu, Jie; Lam, Raymond L.H.; Kaufman, Keith D.; Engel, Samuel S.; Bruzone, Santiago Oscar; Coronel, Maria Jimena; Gruz, Fernando M.; MacKinnon, Ignacio; George, Jacob; Muller, Kate; Lee, Samuel S. (2023-06-22). "A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease". Journal of Hepatology. 79 (4): 888–897. doi: 10.1016/j.jhep.2023.05.013 . hdl: 10261/349752 . ISSN 0168-8278. PMID 37355043.

[2] Novikoff, Aaron; Müller, Timo D. (July 2023). "The molecular pharmacology of glucagon agonists in diabetes and obesity". Peptides. 165 171003. doi: 10.1016/j.peptides.2023.171003 . PMC 10265134 . PMID 36997003.

[3] Zhihong, Yao; Chen, Wang; Qianqian, Zhu; Lidan, Sun; Qiang, Zhou; Jing, Han; Wenxi, Wang; Bhawal, Ruchika (April 2023). "Emerging roles of oxyntomodulin-based glucagon-like peptide-1/glucagon co-agonist analogs in diabetes and obesity". Peptides. 162 170955. doi:10.1016/j.peptides.2023.170955. PMID 36669563. S2CID 255969171.

[4] Jepsen, Mathies M.; Christensen, Mikkel B. (3 July 2021). "Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity". Expert Opinion on Emerging Drugs. 26 (3): 231–243. doi:10.1080/14728214.2021.1947240. PMID 34176426. S2CID 235661514.

[1]

[2]

[3]

[4]